Nevro Price to Free Cash Flow Ratio 2013-2022 | NVRO

Historical price to free cash flow ratio values for Nevro (NVRO) since 2013. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Nevro Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2023-02-03 39.79 100.56
2022-09-30 46.60 $0.40 117.77
2022-06-30 43.83 $-2.29 0.00
2022-03-31 72.33 $-2.14 0.00
2021-12-31 81.07 $-1.56 0.00
2021-09-30 116.38 $-0.80 0.00
2021-06-30 165.79 $0.04 4492.95
2021-03-31 139.50 $-0.23 0.00
2020-12-31 173.10 $-0.14 0.00
2020-09-30 139.30 $-0.90 0.00
2020-06-30 119.47 $-1.32 0.00
2020-03-31 99.98 $-1.20 0.00
2019-12-31 117.54 $-1.74 0.00
2019-09-30 85.97 $-1.10 0.00
2019-06-30 64.83 $-1.21 0.00
2019-03-31 62.51 $-0.82 0.00
2018-12-31 38.89 $-0.46 0.00
2018-09-30 57.00 $-0.76 0.00
2018-06-30 79.85 $-0.37 0.00
2018-03-31 86.67 $-0.51 0.00
2017-12-31 69.04 $-0.63 0.00
2017-09-30 90.88 $-1.07 0.00
2017-06-30 74.43 $-1.32 0.00
2017-03-31 93.70 $-1.56 0.00
2016-12-31 72.66 $-2.17 0.00
2016-09-30 104.39 $-2.89 0.00
2016-06-30 73.76 $-3.80 0.00
2016-03-31 56.26 $-4.39 0.00
2015-12-31 67.51 $-3.97 0.00
2015-09-30 46.39 $-9.82 0.00
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $1.410B $0.387B
Nevro Corp. is a medical device company which engages in developing and commercializing a neuromodulation platform for the treatment of chronic pain, primarily in the leg. The company is known for developing and commercializing the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. Additionally, the company's HF10 therapy provides long-lasting relief from chronic back and leg pain. Nevro's flagship Senza SCS system has been consistently driving the top line. Since its commercial launch in the United States, the system raked in significant revenues. These apart, Senza is commercially available in Europe since 2010 and in Australia since 2011.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $230.517B 25.29
Edwards Lifesciences (EW) United States $50.772B 33.11
Alcon (ALC) Switzerland $37.369B 32.17
STERIS (STE) Ireland $21.864B 27.21
Teleflex (TFX) United States $12.124B 19.67
Fresenius Medical Care AG KGaA (FMS) Germany $11.123B 11.16
Penumbra (PEN) United States $9.913B 2372.91
Globus Medical (GMED) United States $7.950B 40.42
Glaukos (GKOS) United States $2.458B 0.00
Integer Holdings (ITGR) United States $2.435B 19.55
AVANOS MEDICAL, INC (AVNS) United States $1.469B 20.92
Paragon 28 (FNA) United States $1.346B 0.00
Artivion (AORT) United States $0.566B 0.00